Beutler; Bruce

Patent Applications and Registrations

Patent applications and USPTO patent grants for Beutler; Bruce.The latest application filed is for "compositions and methods for cancer therapy".

Company Profile

3.12.14

Beutler; Bruce - Austin TX
Beutler; Bruce - lrving TX
Beutler; Bruce - Dallas TX
Beutler; Bruce - Irving TX
Beutler; Bruce - San Diego CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compositions and methods for cancer therapy Grant 11,365,250 - Beutler , et al. June 21, 2	2022-06-21
Compositions And Methods For Cancer Therapy App 20220162303 - Beutler; Bruce ; et al.	2022-05-26
Adjuvant Effect Of The Tlr1/2 Agonist Diprovocim Synergizes With Checkpoint-inhibiting Antibodies To Eliminate Disease App 20210315992 - Beutler; Bruce ; et al.	2021-10-14
Methods and Compositions for Regulating an Immune Response App 20210269519 - Beutler; Bruce ; et al.	2021-09-02
Diprovocims: a new and potent class of TLR agonists Grant 11,040,959 - Beutler , et al. June 22, 2	2021-06-22
Compositions and Methods for Cancer Therapy App 20200385459 - Beutler; Bruce ; et al.	2020-12-10
Diprovocims: A New And Potent Class Of Tlr Agonists App 20200207742 - Beutler; Bruce ; et al.	2020-07-02
TLR-independent small molecule adjuvants Grant 9,918,959 - Boger , et al. March 20, 2	2018-03-20
Tlr-independent Small Molecule Adjuvants App 20170224653 - Boger; Dale L. ; et al.	2017-08-10
Neoseptins: small molecule adjuvants Grant 9,649,373 - Beutler , et al. May 16, 2	2017-05-16
Neoseptins: Small Molecule Adjuvants App 20160000907 - BEUTLER; Bruce ; et al.	2016-01-07
Compositions And Methods For Modulating Cells Via Cd14 And Toll-like Receptor 4 Signaling Pathway App 20110214194 - Beutler; Bruce ; et al.	2011-09-01
Compositions and methods for treatment of autoimmune and related diseases Grant 7,705,199 - Beutler , et al. April 27, 2	2010-04-27
Compositions and methods for treating gram positive bacterial infection in a mammalian subject App 20090202519 - Beutler; Bruce ; et al.	2009-08-13
Compositions and Methods for Treatment of Autoimmune and Related Diseases App 20080152643 - Beutler; Bruce ; et al.	2008-06-26
Compositions and methods for treatment of immune-related disease App 20070243575 - Hoebe; Kasper ; et al.	2007-10-18
Compositions and methods for treating Gram positive bacterial infection in a mammalian subject App 20070231335 - Beutler; Bruce ; et al.	2007-10-04
Compositions and methods for treatment of autoimmune and related diseases App 20060265767 - Beutler; Bruce ; et al.	2006-11-23
Compositions and methods for modulating cells via CD14 and toll-like receptor 4 signaling pathway App 20060257411 - Beutler; Bruce ; et al.	2006-11-16
Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.) Grant 6,046,309 - Cerami , et al. April 4, 2	2000-04-04
Composition comprising antibody to macrophage-derived inflammatory mediator (MIP-.alpha. 1 and MIP-1.beta.) Grant 6,019,969 - Cerami , et al. February 1, 2	2000-02-01
Method for measuring the binding sites for macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.) Grant 5,989,836 - Cerami , et al. November 23, 1	1999-11-23
Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.) Grant 5,863,535 - Cerami , et al. January 26, 1	1999-01-26
Antibody to macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.) Grant 5,760,186 - Cerami , et al. June 2, 1	1998-06-02
Macrophage-derived inflammatory mediator (MIP-1.alpha. and MIP-1.beta.) Grant 5,616,688 - Cerami , et al. April 1, 1	1997-04-01

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.